BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Jennerex, Inc. 

One Market Street
Spear Tower, Suite 2260
San Francisco  California  94105  U.S.A.
Phone: 415-281-8886 Fax:


SEARCH JOBS










 Company News
SillaJen Biotherapeutics Announces Completion Of Name Change Following Acquisition Of Jennerex, Inc. 6/19/2014 10:38:27 AM
SillaJen Grabs Jennerex, Inc. for $150 Million 11/26/2013 6:53:02 AM
Jennerex, Inc. Announces That Its Phase 2 Study of Pexa-Vec in Second-Line Advanced Liver Cancer Did Not Meet Its Primary Endpoint 9/3/2013 2:08:23 PM
Jennerex, Inc. to Present at the 33rd Annual Canaccord Genuity Growth Conference 8/12/2013 6:46:56 AM
TRANSGENE (TRGNY) Announces a Follow-on Investment in Jennerex, Inc. 5/28/2013 9:51:16 AM
Jennerex, Inc. Completes $21.6 Million Private Placement 5/23/2013 7:30:07 AM
Jennerex, Inc. Announces Completion of Enrollment in Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer 5/21/2013 11:16:33 AM
Jennerex, Inc. Announces Science Translational Medicine Publication Highlighting Pexa-Vec's Ability to Induce Functional Anti-Cancer Immunity in Patients With Diverse Tumor Types 5/16/2013 12:10:12 PM
Jennerex, Inc. Granted FDA Orphan Drug Designation for Pexa-Vec in Hepatocellular Carcinoma (HCC) 5/9/2013 11:03:16 AM
Jennerex, Inc. Announces Presentation of Data Demonstrating Pexa-Vec's Vascular Targeting Mechanism 4/9/2013 11:41:49 AM
1234567